Breast Cancer
Conditions
Keywords
breast cancer screening, tomosynthesis, digital mammography
Brief summary
The study aims at evaluating the introduction of tomosynthesis in mammography screening, analyzing the benefits, disadvantages and feasibility in current clinical practice. It involves women aged 45-46 that will be divided, by drawing lots, into two groups: one group will do the 2D digital mammography (control group), while the other group (intervention group) will do tomosynthesis. In the intervention group the 2D two-dimensional mammography will be reconstructed starting from tomosynthesis without exposing women to other radiation.
Detailed description
The IMPETO trial is a population-based, multicentre, randomised trial aimed at evaluating the clinical accuracy of Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM) compared to standard two-dimensional digital mammography alone (2D) in a screening programme. 45-46 year-old women resident in the screening centre catchment area of Florence and South-Est Local Health Unit are invited to attend for mammography screening and asked for informed consent to be included in the study. Women are then randomly allocated either to an usual care group (2D mammography) or to the intervention group. In the intervention group, DBT combined with sDM is proposed in order to reduce radiation exposure. The next year women of both groups will be invited to attend the usual screening examination (2D mammography). The enrolment will last 12-18 months; the whole study 36 months. The estimated sample size is 6000 women, 3000 per arm. Data will be pooled with the trial Screening for Breast Cancer With Digital Breast Tomosynthesis, ClinicalTrials.gov Identifier: NCT02698202.
Interventions
DIAGNOSTIC_TESTTomosynthesis
DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
DIAGNOSTIC_TEST2D mammography
2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
Sponsors
Cancer Prevention and Research Institute, Italy
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 46 Years
Healthy volunteers
Yes
Inclusion criteria
* 45-46 years old women resident in the screening area
Exclusion criteria
* previous breast cancer * written refusal to participate in the screening programme * pregnancy, breastfeeding * presence of prostheses; * ongoing chemotherapy; * impossibility to submit the informed consent for linguistic problems or for inability of women to provide informed consent; * verified presence of BRCA1 - BRCA2 (Breast Related Cancer Antigens 1 - Breast Related Cancer Antigens 2) genetic mutation or involvement in surveillance path for heredo-familial tumor; * previous known tomosynthesis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the cumulative incidence of advanced screen-detected cancers (T2 +) and the cumulative incidence of advanced interval cancers (T2 +) | three years | number of T2+ screen-detected cancers divided by all screened women at subsequent round of screening and number of T2+ interval cancers divided by all screened women at subsequent round of screening. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| recall rate | two years | number of women recalled to perform 2nd level assessments) for invasive tests and for non-invasive examinations in the two arms divided by the number of screened women |
| detection rate | two years | number of breast cancer cases (invasive and in situ forms) divided by the number of screened women (per 1,000) |
| benign biopsies rate | two years | number of benign biopsies divided by the total number of biopsies |
| cost analysis | two years | an activity based cost analysis will be performed in order to obtain the real costs of DBT screening pathway. |
Countries
Italy
Contacts
Primary ContactPaola Mantellini, MDr
Outcome results
None listed